In January 2023 the decision to discontinue the remaining presentations of Insuman® regular human, isophane and isophane pre-mixed insulins in the UK, phased over the following 6 months, was announced.
Unfortunately, due to unexpected capacity and component part constraints at plant, Sanofi is expected to discontinue the following products by the end of February 2023:
- Insuman® Basal 100 IU/ml suspension for injection in a cartridge (Insulin isophane human)
- Insuman® Comb 25 100 IU/ml suspension for injection in a cartridge (Insulin biphasic isophane human)
As it will not be an option to continue patients on treatment with these Insuman® presentation past
this date, alternative treatment options should be considered for any remaining patients, under the
supervision of their prescribing clinician.
The supply exhaustion dates of the other presentations of Insuman® currently being discontinued are:
3. Insuman® Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen (Insulin isophane human) - Expected End of Supply: June 2023
4. Insuman® Comb 25 SoloStar 100 IU/ml suspension for injection in a pre-filled pen (Insulin biphasic isophane human) - Expected End of Supply: June 2023
5. Insuman® Rapid 100 IU/ml solution for injection in a cartridge (Insulin soluble human) - Expected End of Supply: May 2023
Expected end supply dates are only approximate and supply may be exhausted before/after these dates based on future patient demand.
If you have any questions regarding this information or would like to speak to a member of the Sanofi medical team, please contact the medical information department who can arrange that:
- Medical Information at Sanofi, 410 Thames Valley Park Drive, Reading, RG6 1PT, UK
- Tel: +44 (0) 800 035 2525
- Email: uk-medicalinformation@sanofi.com
For questions relating to ordering, please contact:
- Sanofi Customer Services Tel: +44 (0) 800 854 430 (Mon-Fri 9am – 5pm).
Sanofi apologies for any inconvenience that this discontinuation and stock exhaustion may cause you or your patients.
